Icure Pharmaceutical Finalizes Director Candidates for EGM, No Shareholder Value Impact


  • Icure Pharmaceutical has corrected its previous disclosure regarding the temporary shareholder meeting scheduled for August 6, 2026, by finalizing the director candidates for election.
  • The candidates are inside directors Lee Jae-won and Jo A-in, and independent directors Hwang Cheol-min and Hong Seong-yong.
  • This correction is purely procedural, updating the status from undefined to confirmed, with no changes to capital structure or financials.
  • The company has not disclosed any additional capital raising or capital structure modification plans.
  • [AI Summary]This amended disclosure finalizes the director nominee slate for the upcoming EGM, representing a routine governance update with zero financial impact. While the new directors bring relevant experience, the disclosure does not trigger any immediate shareholder value event.

KOSDAQ Filing Information


  • [Correction of Description] Resolution on Convening of General Meeting of Shareholders (Extraordinary General Meeting)
  • Company: Icure Pharmaceutical (175250)
  • Submission: Icure Pharmaceutical Incorporation
  • Under KRX KOSDAQ Market Division

  • Shares: 37,558,368
  • Price: 2,170 KRW
  • Market Cap: 81.5 B KRW